Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | FURIN | P09958 | 5/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297530 | 1.00 | OPRK1 (0.40) | OPRK1OPRM1FURINNMT2NMT1 | |
| SCHEMBL30530913 | 0.94 | FURIN (0.43) | FURINNMT2NMT1CPB2 | |
| SCHEMBL29630629 | 0.90 | CPB2 (0.46) | OPRK1OPRM1NMT2NMT1CPB2 | |
| SCHEMBL31343441 | 0.89 | NMT2 (0.41) | OPRK1OPRM1FURINNMT2NMT1 | |
| SCHEMBL29475360 | 0.89 | CPB2 (0.47) | OPRK1OPRM1CPB2ERAP2ERAP1 | |
| SCHEMBL31232419 | 0.88 | NPY4R (0.48) | OPRK1FURINNMT2NMT1CPB2 | |
| SCHEMBL30683244 | 0.86 | ALDH1A1 (0.42) | — | |
| SCHEMBL31257001 | 0.86 | CPB2 (0.45) | OPRK1OPRM1CPB2ERAP2ERAP1 | |
| SCHEMBL29530892 | 0.86 | FURIN (0.46) | FURINNMT2NMT1 | |
| SCHEMBL32681781 | 0.85 | NPY4R (0.49) | OPRK1NMT2NMT1CPB2ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254198-A1 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | 3H BIO. CO., LTD. (KR) | 2024-08-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254198-A1 | PEPTIDE USED FOR IMMUNOTHERAPEUTICS | CD4, IL2, ICOS | OPRK1 4088/4885OPRM1 3251/4885FURIN 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.